Advanced HER2-Positive Gastric Cancer - a podcast by ReachMD

CME credits: 0.25

Valid until: 13-05-2022

Claim your CME credit at https://reachmd.com/programs/cme/advanced-her2-positive-gastric-cancer/12507/

Do you face clinical challenges when managing patients with advanced HER2-positive gastric cancer? You’re not alone. Advanced gastroesophageal cancers remain among the most difficult cancers for clinicians to manage. One of the many challenges to optimizing patient outcomes is a relative lack of familiarity with practice standards regarding HER2-positive disease. While HER2 is an oncogenic driver in gastroesophageal cancers, it does not appear to act as a predictive biomarker in quite the same way as it does in breast cancer. However, there are ways to fully optimize anti-HER2 therapy in gastroesophageal cancers. Join us as Dr. Daniel Catenacci and Dr. Yelena Janjigian demystify HER2-positive gastroesophageal cancers and provide insights for the integration of personalized therapeutic approaches for these patients.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD